JP4155522B2 - オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体 - Google Patents

オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体 Download PDF

Info

Publication number
JP4155522B2
JP4155522B2 JP2003538138A JP2003538138A JP4155522B2 JP 4155522 B2 JP4155522 B2 JP 4155522B2 JP 2003538138 A JP2003538138 A JP 2003538138A JP 2003538138 A JP2003538138 A JP 2003538138A JP 4155522 B2 JP4155522 B2 JP 4155522B2
Authority
JP
Japan
Prior art keywords
exo
aza
bicyclo
ethyl
hex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003538138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511545A (ja
JP2005511545A5 (enExample
Inventor
マクハーディー，スタントン・ファースト
リラス，スピロス
ヘック，スティーヴン・ドナルド
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2005511545A publication Critical patent/JP2005511545A/ja
Publication of JP2005511545A5 publication Critical patent/JP2005511545A5/ja
Application granted granted Critical
Publication of JP4155522B2 publication Critical patent/JP4155522B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003538138A 2001-10-22 2002-09-09 オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体 Expired - Fee Related JP4155522B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33851101P 2001-10-22 2001-10-22
PCT/IB2002/003668 WO2003035622A1 (en) 2001-10-22 2002-09-09 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007272602A Division JP2008069169A (ja) 2001-10-22 2007-10-19 オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体

Publications (3)

Publication Number Publication Date
JP2005511545A JP2005511545A (ja) 2005-04-28
JP2005511545A5 JP2005511545A5 (enExample) 2007-12-13
JP4155522B2 true JP4155522B2 (ja) 2008-09-24

Family

ID=23325099

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003538138A Expired - Fee Related JP4155522B2 (ja) 2001-10-22 2002-09-09 オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体
JP2007272602A Pending JP2008069169A (ja) 2001-10-22 2007-10-19 オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007272602A Pending JP2008069169A (ja) 2001-10-22 2007-10-19 オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体

Country Status (42)

Country Link
US (3) US7049335B2 (enExample)
EP (1) EP1440059B1 (enExample)
JP (2) JP4155522B2 (enExample)
KR (1) KR100621292B1 (enExample)
CN (1) CN100368398C (enExample)
AP (1) AP1816A (enExample)
AR (1) AR036905A1 (enExample)
AT (1) ATE392415T1 (enExample)
AU (1) AU2002329557B2 (enExample)
BR (1) BR0213464A (enExample)
CA (1) CA2463264C (enExample)
CR (1) CR7317A (enExample)
DE (1) DE60226161T2 (enExample)
DK (1) DK1440059T3 (enExample)
EA (1) EA006708B1 (enExample)
EC (1) ECSP045077A (enExample)
ES (1) ES2302839T3 (enExample)
GE (1) GEP20084300B (enExample)
GT (1) GT200200216A (enExample)
HN (1) HN2002000299A (enExample)
HR (1) HRP20040288A2 (enExample)
HU (1) HUP0401884A2 (enExample)
IL (2) IL161157A0 (enExample)
IS (1) IS7187A (enExample)
MA (1) MA27141A1 (enExample)
MX (1) MXPA04003730A (enExample)
MY (1) MY136580A (enExample)
NO (1) NO329092B1 (enExample)
NZ (1) NZ531807A (enExample)
OA (1) OA12711A (enExample)
PA (1) PA8556701A1 (enExample)
PE (1) PE20030610A1 (enExample)
PL (1) PL368919A1 (enExample)
PT (1) PT1440059E (enExample)
PY (1) PY0225353A (enExample)
RS (1) RS25104A (enExample)
SI (1) SI1440059T1 (enExample)
SV (1) SV2004001363A (enExample)
TN (1) TNSN04071A1 (enExample)
UA (1) UA75714C2 (enExample)
WO (1) WO2003035622A1 (enExample)
ZA (1) ZA200402172B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0209129A (pt) 2001-04-18 2005-12-20 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
DE60226161T2 (de) * 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
MXPA05011070A (es) * 2003-04-14 2005-12-12 Pfizer Prod Inc Derivados de 3-azabiciclo [3.2.1] octano.
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7153976B2 (en) * 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound
ES2634841T3 (es) * 2003-10-14 2017-09-29 Pfizer Products Inc. Derivados bicíclicos [3.1.0] como inhibidores del transportador de glicina
EP1675829A1 (en) * 2003-10-16 2006-07-05 Pfizer Products Inc. Preparation of 3-azabicyclo [3.1.0] hexane derivatives
ATE451364T1 (de) 2004-02-23 2009-12-15 Glaxo Group Ltd Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
AU2005219785B2 (en) * 2004-03-05 2010-05-27 Msd K.K. Cycloalkanopyridine derivative
EP1837022A4 (en) * 2004-12-14 2009-12-16 Toray Industries INDOLOMORPHINANE DERIVATIVE WITH CARBOXY IN 6 'POSITION
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2008075162A2 (en) * 2006-12-15 2008-06-26 Pfizer Limited Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
ES2390195T3 (es) * 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
WO2009029253A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
CA2927527C (en) * 2013-11-20 2021-06-01 Sanwa Kagaku Kenkyusho Co., Ltd. Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof as u-opioid receptor antagonist
HK1246778A1 (zh) * 2015-05-20 2018-09-14 株式会社三和化学研究所 一种新型的3-氮杂双环[3.1.0]己烷衍生物的盐的晶体以及其医药应用
EP3590511A4 (en) 2017-03-02 2020-09-02 Sanwa Kagaku Kenkyusho Co., Ltd THERAPEUTIC AGENT FOR DISORDERS RELATED TO THE CONSUMPTION OF ALCOHOL

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2099214A (en) * 1937-11-16 Process fob forming the sulphuric
US2099216A (en) * 1934-05-04 1937-11-16 Frederick H Nass Metal testing machine
US3004340A (en) * 1959-09-24 1961-10-17 Bernice L Collins Kitchen utensil
US3078282A (en) * 1960-01-02 1963-02-19 Bayer Ag Anthraquinone dyestuffs
ATE110057T1 (de) 1987-04-16 1994-09-15 Lilly Co Eli Piperidine als opioid-antagoniste.
JPH04155522A (ja) * 1990-10-19 1992-05-28 Nec Corp ファースト・イン・ランダム・アウト回路
ZA922180B (en) 1991-03-29 1993-09-27 Lilly Co Eli Piperidine derivatives
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
GB9725114D0 (en) * 1997-11-28 1998-01-28 Pfizer Ltd Treatment of pruritus
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912415D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US20020064825A1 (en) * 2000-05-19 2002-05-30 Lewis Marilyn Evelyn Novel polypeptide
US20030207876A1 (en) * 2000-06-23 2003-11-06 Banks Bernard Joseph 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
DE10042885A1 (de) * 2000-08-31 2002-03-14 Heidelberger Druckmasch Ag Bogentransportzylinder
DE60226161T2 (de) 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
AU2003239389A1 (en) 2002-05-30 2003-12-19 Eli Lilly And Company Opioid receptor antagonists
US7056930B2 (en) * 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
US20040204453A1 (en) * 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7153976B2 (en) * 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound

Also Published As

Publication number Publication date
CR7317A (es) 2006-08-09
AU2002329557B2 (en) 2008-07-31
US20070054950A1 (en) 2007-03-08
EP1440059A1 (en) 2004-07-28
OA12711A (en) 2006-06-27
MA27141A1 (fr) 2005-01-03
MY136580A (en) 2008-10-31
GT200200216A (es) 2003-05-23
BR0213464A (pt) 2004-11-09
PE20030610A1 (es) 2003-07-12
EA006708B1 (ru) 2006-02-24
SI1440059T1 (sl) 2008-08-31
ZA200402172B (en) 2006-09-27
HK1072052A1 (zh) 2005-08-12
GEP20084300B (en) 2008-02-11
EA200400467A1 (ru) 2004-08-26
IL161157A (en) 2009-09-01
AP1816A (en) 2008-01-04
US20050171178A1 (en) 2005-08-04
IS7187A (is) 2004-03-18
AR036905A1 (es) 2004-10-13
IL161157A0 (en) 2004-08-31
ATE392415T1 (de) 2008-05-15
CA2463264C (en) 2009-05-26
MXPA04003730A (es) 2004-07-23
JP2005511545A (ja) 2005-04-28
PT1440059E (pt) 2008-05-16
CN100368398C (zh) 2008-02-13
NZ531807A (en) 2006-03-31
PY0225353A (es) 2004-05-03
TNSN04071A1 (fr) 2006-06-01
KR20040048984A (ko) 2004-06-10
UA75714C2 (en) 2006-05-15
ES2302839T3 (es) 2008-08-01
AP2004003007A0 (en) 2004-06-30
EP1440059B1 (en) 2008-04-16
DK1440059T3 (da) 2008-07-14
SV2004001363A (es) 2004-02-24
CN1610664A (zh) 2005-04-27
NO20041626L (no) 2004-05-26
KR100621292B1 (ko) 2006-09-13
DE60226161D1 (de) 2008-05-29
DE60226161T2 (de) 2009-07-02
HN2002000299A (es) 2002-11-21
PL368919A1 (en) 2005-04-04
PA8556701A1 (es) 2003-07-28
RS25104A (sr) 2007-02-05
NO329092B1 (no) 2010-08-23
JP2008069169A (ja) 2008-03-27
ECSP045077A (es) 2004-05-28
US20030087898A1 (en) 2003-05-08
HRP20040288A2 (en) 2004-12-31
HUP0401884A2 (hu) 2005-01-28
WO2003035622A1 (en) 2003-05-01
US7049335B2 (en) 2006-05-23
CA2463264A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
JP2008069169A (ja) オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体
USRE40838E1 (en) 2-azabicyclo[3.3.1]nonane derivatives
AU2002329557A1 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
JP2006522792A (ja) ４−フェニル−ピペリジン化合物およびそのオピオイド受容体のモジュレーターとしての使用
US7241887B2 (en) 3-azabicyclo[3.2.1]octane derivatives
UA73756C2 (en) HALOGEN-SUBSTITUTED 4-PHENYL-1-PIPERAZIN, PIPERIDIN AND TETRAHYDROPIRIDINE û DERIVATIVES A PHARMACEUTICAL COMPOSITION BASED THEREON, THEIR APPLICATION FOR PRODUCING MEDICAMENT, AND A METHOD FOR THE TREATMENT OF PSYCHOSIS
US20040116467A1 (en) Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
HUP0303316A2 (hu) Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények
JPH08277267A (ja) 抗うつ作用を有するナフチル−モナジンのヘテロアリールアミノアルキル誘導体
TW200526578A (en) Process for preparing an azabicyclo[3.1.0]hexane compound
HK1072052B (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080328

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080702

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080704

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110718

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110718

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120718

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130718

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees